- Bio-Rad Laboratories reported Q3 2026 sales of US$656.4 million and net income of US$458.6 million, with earnings per share from continuing operations above US$17 on both a basic and diluted basis.
- Clinical Diagnostics and Droplet Digital PCR drove the first quarter of currency neutral revenue growth in 2026, alongside firmer operating margins and reaffirmed full-year guidance despite ongoing pressures in some international markets.
- We will now look at how Bio-Rad Laboratories' return to currency neutral revenue growth could reshape the broader investment narrative.
Bio-Rad Laboratories Investment Narrative Recap
To own Bio-Rad Laboratories, you need to be comfortable with a slow top line and a heavier focus on execution than on headline growth. The near term bull case hinges on Clinical Diagnostics and Droplet Digital PCR staying resilient enough to support margins while management pushes cost discipline and productivity. The latest quarter showed that modest currency neutral growth and firmer profitability are at least compatible with that thesis.
The biggest immediate catalyst is whether Bio-Rad can translate its ddPCR momentum and AI assisted tools into steadier organic growth while keeping operating margins on an upward path. The main risk has not gone away. Ongoing pressure in instrument demand and Chinese diagnostics pricing could reassert itself and cap both revenue and margin progress if conditions tighten again.
The most relevant new data point for you is the Q3 2026 earnings print. Bio-Rad Laboratories reported US$656.4 million in quarterly sales with basic EPS from continuing operations of US$17.13, and management reaffirmed full year guidance. That combination of revenue stability, profitability and an unchanged outlook makes the quarter a clean operational check-in for the existing story rather than a reset.
Looking under the hood, currency neutral growth was modest at 0.7%, but Clinical Diagnostics returned to expansion and ddPCR instruments delivered another period of strong demand. Non GAAP operating margin of 12.8% and non GAAP EPS of US$2.65 gave management enough confidence to keep margin ambitions intact despite a US$49.8 million impairment of purchased intangibles. For investors, the key question is whether that early traction in diagnostics, AI enabled platforms and consumables can offset policy, funding and competition risks that still sit in the background.
Bio-Rad Laboratories' current analyst narrative points to forecast revenues of US$2.7b and earnings of US$224.0 million by 2029, built on assumed yearly revenue growth of 1.5% and an earnings increase of about US$1.6 million from US$222.4 million today.
Uncover why Bio-Rad Laboratories' fair value indicates a 14% potential downside to its current price, leaving little room for error.
Exploring Other Perspectives
One bearish twist you might explore is the concern that Bio-Rad Laboratories needs to squeeze more earnings out of its cost savings push. The lowest analysts were modelling roughly flat revenue at about US$2.6b and only a modest earnings lift to US$228.5 million by 2029. Those expectations were set before this Q3 report, so both stories may now shift.
Explore another Bio-Rad Laboratories fair value estimate, including one that suggests as much as 22% downside from the current price!
The Verdict Is Yours
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Bio-Rad Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Bio-Rad Laboratories. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Bio-Rad Laboratories' overall financial health at a glance.
Looking For More Investment Ideas Beyond Bio-Rad Laboratories?
Once you have a handle on Bio-Rad Laboratories, it can help to set it alongside other opportunities so you can judge risk, income potential and valuation in context. The Simply Wall St Screener lets you filter the market by fundamentals in a few clicks, so you can build a watchlist that genuinely fits your goals rather than relying on headlines or hype.
- If capital preservation and steadier profiles matter most to you, start with a group of 29 resilient stocks with low risk scores that may suit a more cautious approach.
- For investors hunting for quality at a reasonable price, scan a focused set of 39 high quality undervalued stocks that combine fundamentals with what might be appealing valuations.
- Income focused readers can zero in on potential yield opportunities by filtering for 8 dividend fortresses and checking which payouts line up with their risk tolerance.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com